Breaking Finance News

A statement released earlier today by Leerink Partners about Reata Pharmaceuticals (NASDAQ:RETA) bumps the target price to $43.00

Stating a potential upside of 0.44%, Leerink Partners upped the price target of Reata Pharmaceuticals (NASDAQ:RETA) to $43.00

On 07/25/2017, Citigroup released a statement on Reata Pharmaceuticals (NASDAQ:RETA) upped the target price from $39.00 to $87.00 that suggested an upside of 1.45%.

Having a price of $29.77, Reata Pharmaceuticals (NASDAQ:RETA) traded 2.40% higher on the day. With the last close up 13.90% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the same period. Reata Pharmaceuticals has recorded a 50-day average of $28.88 and a two hundred day average of $26.77. Volume of trade was down over the average, with 68,355 shares of RETA changing hands under the typical 205,709

Performance Chart

Reata Pharmaceuticals (NASDAQ:RETA)

With a total market value of $0, Reata Pharmaceuticals has with a one year low of $18.51 and a one year high of $41.60 .

More About Reata Pharmaceuticals (NASDAQ:RETA)

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.